ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
Advances a new formulation with improved stability in the clinic Single ascending dose phase successfully completed, multiple ascending dose phase underway Melbourne, Australia, 27 August 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has […]